Cite

HARVARD Citation

    Wu, Y. et al. (n.d.). 339TiPPACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC. Annals of oncology. p. . [Online]. 
  
Back to record